LS-1727
Experimental drug
| LS-1727 | |
|---|---|
| File:LS-1727 structure.png | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | 123456-78-9 |
| PubChem | 123456 |
| DrugBank | |
| ChemSpider | 123456 |
| KEGG | D12345 |
LS-1727 is an experimental pharmaceutical drug that has been studied for its potential effects on the central nervous system. It is classified as a urea derivative and has been primarily investigated for its anxiolytic and antidepressant properties.
Chemical Structure and Properties[edit | edit source]
LS-1727 is a chemical compound with the IUPAC name 1-(4-chlorophenyl)-3-(2,6-dimethylphenyl)urea. The compound consists of a urea moiety linked to a 4-chlorophenyl group and a 2,6-dimethylphenyl group. The presence of the chlorine atom and the methyl groups contribute to its unique pharmacological profile.
Pharmacology[edit | edit source]
LS-1727 has been shown to interact with various neurotransmitter systems in the brain. It is believed to modulate the activity of gamma-aminobutyric acid (GABA) receptors, which are involved in the regulation of anxiety and mood. The compound may enhance the inhibitory effects of GABA, leading to its potential anxiolytic and antidepressant effects.
Mechanism of Action[edit | edit source]
The exact mechanism of action of LS-1727 is not fully understood. However, it is hypothesized that the compound acts as a positive allosteric modulator of GABAA receptors. This modulation increases the inhibitory neurotransmission in the brain, which can result in reduced anxiety and improved mood.
Potential Therapeutic Uses[edit | edit source]
LS-1727 is being researched for its potential use in treating anxiety disorders and depression. Its ability to modulate GABAergic activity makes it a candidate for conditions where these neurotransmitter systems are dysregulated.
Research and Development[edit | edit source]
As of the latest updates, LS-1727 is still in the preclinical stages of development. Studies are ongoing to determine its safety, efficacy, and pharmacokinetics. Further research is needed to fully understand its therapeutic potential and to evaluate its effects in clinical trials.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
